Strategic Therapeutic Focus: Gastroenterology (GI) and Central Nervous System (CNS)

Gastrointestinale system

Natural and Pharmaceutical Chemical Drugs

Co-formulation research
Development Status
33%

Medical Apparatus and Instruments

medical apparatus and instruments
Development Status
50%

Nursing Products

approval expected within the year.
Development Status
70%

Our GI portfolio is built on three synergistic pillars:
(1) natural-origin therapeutics with favorable safety profiles that address unmet needs in first-line treatment;
(2) medical devices enabling targeted, minimally invasive interventions;
(3) post-treatment care products that support the full continuum of patient management. Together, these pillars create a differentiated, end-to-end platform in gastroenterology that is difficult to replicate.

Central Nervous System (CNS)

Insomnia medication- BIC drug

Launched in Japan
License into China
Orexin receptor-based sleep-wake regulation, co-developed with a Japanese partner, addressing addiction and next-day hangover risks associated with current hypnotics.

New Mechanism Asset

NDA
License into China
A triple reuptake inhibitor for ADHD, non-controlled and non-doping, addressing abuse risk, dose-response variability, and the emotional dimension gap of current therapies.

Essential Tremor (ET) – T-type calcium antagonists

PCC
A new selective T-type calcium channel blocker targeting the core tremor-generating neural circuit, with mechanism validated by FDA Breakthrough Therapy Designation (BTD).